People with secondary progressive multiple sclerosis are currently being enrolled in a phase II/III trial outside of the United States that will evaluate the impact of an intravenously administered synthetic peptide that targets a portion of myelin basic protein related to disease progression, according to the manufacturer, BioMS Medical Corp.
PREVIEW